Agios Pharmaceuticals
AGIO
31.79
+0.07
+0.22%
Agios Pharmaceuticals
US · AGIO
#2841 by market cap
Listed 1970
31.79
+0.07
+0.22%
Live - 5344 symbols - heartbeat 402s ago
· 2026-10-07 19:54
After-hours
31.79
0.00%
- Market cap
- 1.90B
- P/E (TTM)i
- -4.53
- P/Bi
- 1.85
- EPSi
- -7.12
- Div yieldi
- 0.00%
- 52W posi
- 40%
Reader sentiment
Are you bullish or bearish on AGIO?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 6 analysts
Buy
Avg price target
52.33 +64.6%
Price target rangecurrent 31.79
Low50.00
Avg52.33
High55.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-21 | BofA Securities | -- | BUY | 50.00 |
| 2026-08-11 | Truist Financial | -- | BUY | -- |
| 2026-08-03 | TD Cowen | -- | BUY | -- |
| 2026-07-31 | Truist Financial | -- | BUY | 39.00 |
| 2026-07-31 | Citi | -- | BUY | 52.00 |
| 2026-07-30 | TD Cowen | -- | BUY | -- |
| 2026-07-30 | BofA Securities | -- | BUY | 46.00 |
| 2026-07-30 | Citi | -- | BUY | 52.00 |
| 2026-07-30 | H.C. Wainwright | -- | BUY | 55.00 |
| 2026-07-22 | BofA Securities | -- | BUY | 46.00 |
| 2026-07-22 | Truist Financial | -- | BUY | -- |
| 2026-07-21 | H.C. Wainwright | -- | BUY | 52.00 |
| 2026-07-13 | H.C. Wainwright | -- | BUY | 54.00 |
| 2026-07-07 | BofA Securities | -- | BUY | 46.00 |
| 2026-07-07 | Truist Financial | -- | BUY | 41.00 |
| 2026-07-07 | Leerink Partners | -- | BUY | -- |
| 2026-07-07 | H.C. Wainwright | -- | BUY | 54.00 |
| 2026-06-16 | TD Cowen | -- | BUY | -- |
| 2026-06-15 | BofA Securities | -- | BUY | 40.00 |
| 2026-06-15 | Truist Financial | -- | BUY | 36.00 |
| 2026-06-15 | H.C. Wainwright | -- | BUY | 54.00 |
| 2026-06-14 | Goldman Sachs | -- | HOLD | 32.00 |
| 2026-06-12 | BofA Securities | -- | BUY | 40.00 |
| 2026-06-11 | J.P. Morgan | -- | HOLD | 31.00 |
| 2026-06-10 | J.P. Morgan | -- | HOLD | 31.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 0 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: RBC Capital moved from Buy to Hold on 2026-02-12.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-02-12 | RBC Capital | BUY → HOLD | 28.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-30 | -- | ±9.54% | -6.46% (in line) |
| 2026/Q1 | 2026-04-29 | -- | ±8.47% | +13.10% (beat) |
| 2025/Q4 | 2026-02-12 | -- | ±12.45% | +1.30% (in line) |
| 2025/Q3 | 2025-10-30 | -- | ±16.58% | +2.91% (in line) |
| 2025/Q2 | 2025-07-31 | -- | ±11.40% | -0.85% (in line) |
| 2025/Q1 | 2025-05-01 | -- | ±21.61% | +4.21% (in line) |
| 2024/Q4 | 2025-02-13 | -- | ±8.31% | +1.49% (in line) |
| 2024/Q3 | 2024-10-31 | -- | ±15.71% | -4.04% (in line) |
| 2024/Q2 | 2024-08-01 | -- | ±13.46% | -4.09% (in line) |
| 2024/Q1 | 2024-05-02 | -- | ±13.65% | +2.73% (in line) |
| 2023/Q4 | 2024-02-15 | -- | ±8.96% | +3.47% (in line) |
| 2023/Q3 | 2023-11-02 | -- | ±9.77% | -1.41% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.